AOD-9604 in Roden — Fat Loss Peptide Research Guide
AOD-9604 research guide for Roden. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers seeking out AOD-9604 in Roden quickly find that local retail options are all but absent from local stores. What this means for Roden researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those verification methods are within reach of all serious researchers. Separating quality AOD-9604 from the rest of the market requires three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. This guide gives Roden researchers the methodology to verify sourcing options methodically and source research-grade AOD-9604 with confidence.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Roden comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. The combination of community consensus and independent COA review is the gold standard for AOD-9604 sourcing — community feedback surfaces recurring issues no single purchase reveals, and vice versa. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order AOD-9604 — ships to Roden
COA-verified · International tracking · Research grade
All use of AOD-9604 in Roden or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should comply with standard research safety practices. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Quality AOD-9604 sourcing directly determines safety outcomes — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. For any individual considering AOD-9604 outside a formal research context: speak with a healthcare professional — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
